Sesen Bio Inc. (SESN) is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer. The company's lead product candidate is Vicinium, an ADC designed to selectively target and kill cancer cells while sparing healthy cells. Vicinium is being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has a high likelihood of progressing and spreading to other parts of the body. In addition to Vicinium, Sesen Bio is also developing a pipeline of other ADC therapies for the treatment of various types of cancer. The company is headquartered in Cambridge, Massachusetts and was founded in 2008.
Sesen Bio Inc. (SESN) is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer. The company's lead product candidate is Vicinium, an ADC designed to selectively target and kill cancer cells while sparing healthy cells. Vicinium is being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), a type of bladder cancer that has a high likelihood of progressing and spreading to other parts of the body. In addition to Vicinium, Sesen Bio is also developing a pipeline of other ADC therapies for the treatment of various types of cancer. The company is headquartered in Cambridge, Massachusetts and was founded in 2008.